
Verteporfin and the donor area: can an eye drug give scar-free healing?
Verteporfin made wounds heal without scars and with new hair follicles in mice and pigs. In humans there are still no published studies showing the same, including in the donor area after a hair transplant.
Verteporfin is a drug for eye disease that in animal studies has made wounds heal without scars, with new hair follicles and normal skin. That's why it's being discussed as a way to help the donor area heal better after FUE and FUT. In humans, only a single patient has so far been described after a hair transplant, and the first two controlled scar trials have not started yet. Use in the scalp is off-label.
What is verteporfin?
Verteporfin (Visudyne) is a drug that has been used for over 20 years against wet age-related macular degeneration, an eye disease. It is given into a vein and activated with laser light in the eye. That makes it a photosensitising drug, and patients have to stay out of strong light for five days after treatment.
The interest from hair medicine comes from something quite different: the drug blocks a signal in cells called YAP. Researchers believe this signal controls whether a wound turns into a scar or into new, normal skin.
What do the animal studies show?
In 2021, a research group at Stanford showed that mechanical tension in a wound switches on YAP in a specific group of connective tissue cells, and that these cells are the ones that make the scar. When they blocked the signal with verteporfin, wounds in mice healed with hair follicles, sweat glands and normal skin strength. No scar formed.
Because mouse skin easily forms new hair follicles in wounds, the group repeated the experiment in pigs, whose skin is much closer to ours. In 2025 they reported that a single treatment right after wounding gave the same result: healing without a scar and with regenerated skin. The findings were supported by experiments with human skin grafted onto mice.
This is solid basic research published in Science and Science Translational Medicine. But it's animals, not humans.
Why is this interesting for the donor area?
With FUE, each extraction leaves a small round wound, and with FUT there is a long suture line at the back of the head. Both heal with scar tissue. The dot scars after FUE are small but numerous, and the strip scar after FUT can become wide if the skin is tight. Scar tissue has no hair follicles, and that's part of why the donor area gets thinner with each session.
The idea is therefore simple: if a drug can make the extraction wounds heal as normal skin, the scars could become less visible and the donor area could hold up better. Some also hope new hair follicles could grow in the wounds, as they did in mice. You can read more about how much the back of the head can give over a lifetime in the guide to donor reserve.
What do we know about verteporfin in humans?
- Scars in general: no study has yet published results for verteporfin against skin scars in humans.
- Registered trials: a trial in Geneva will test the drug against saline in wounds after mole removal in 24 patients. A trial at Odense University Hospital (SCARFREE-001) will test three doses in tummy tuck incisions and in open punch wounds in 12 participants. Neither is recruiting yet, and results from Odense are expected in 2028 at the earliest.
- After hair transplant: one patient is described in a 2025 case report. One side of the donor area received verteporfin, the other didn't, and the authors reported higher density on the treated side after eight weeks. The measurements are poorly described, there was no blinding, and the report appears in a journal not indexed in PubMed. The authors themselves write that more research is needed.
- No controlled hair transplant trial is registered on ClinicalTrials.gov. A US clinic has described a planned pilot with ten patients, but it isn't registered and hadn't started.
Is it safe to use verteporfin in the scalp?
We don't know yet. The approval covers one specific use: an intravenous dose combined with laser light for eye disease. Injecting the drug into the skin is something else, and it is off-label.
The drug makes tissue light-sensitive, and the package leaflet warns of burns if it ends up in tissue that is then exposed to light. The scalp is one of the most sun-exposed parts of the body. Which dose, depth and timing are safe in human skin has not been mapped. On top of that, there has been a long-running global shortage of verteporfin, and what supply exists is prioritised for eye patients.
What should you ask if a clinic offers verteporfin?
- Which published human studies are you basing this on, and how many patients have been followed up?
- Is the treatment part of a registered trial with ethical approval?
- What dose is used, and how is the scalp protected from light in the first few days?
- Does the treatment cost extra, and what happens if it has no effect?
An honest answer is that verteporfin is promising but experimental. A clinic promising scar-free healing or new hair follicles in the donor area is promising more than research can show today. The same goes for claims of an "unlimited donor area".
What can you do for your donor area today?
What actually protects the donor area now is good planning and gentle technique: extraction that stays within the safe zone, small punches, spread-out harvesting and a graft count that suits what the back of your head can give. After the procedure, it's about the right aftercare in the first few weeks.
Read more about research on the donor area and about aftercare week by week.
Sources
- Mascharak S, desJardins-Park HE, Davitt MF, et al., Longaker MT. Preventing Engrailed-1 activation in fibroblasts yields wound regeneration without scarring. Science, 2021;372(6540):eaba2374. pubmed.ncbi.nlm.nih.gov/33888614
- Mascharak S, Talbott HE, Januszyk M, et al., Longaker MT. Multi-omic analysis reveals divergent molecular events in scarring and regenerative wound healing. Cell Stem Cell, 2022;29(2):315-327. pubmed.ncbi.nlm.nih.gov/35077667
- Mascharak S, Griffin M, Talbott HE, et al., Longaker MT. Inhibiting mechanotransduction prevents scarring and yields regeneration in a large animal model. Science Translational Medicine, 2025;17(786). pubmed.ncbi.nlm.nih.gov/39970235
- Clark RAF. To Scar or Not to Scar. New England Journal of Medicine, 2021;385(5):469-471. pubmed.ncbi.nlm.nih.gov/34320296
- Toyos M, Toyos R, Toyos A. Use of Verteporfin to Regrow Hair and Reduce Fibrosis after Transplantation. Journal of Dermatology Research and Therapy, 2025;11:131 (not indexed in PubMed). doi:10.23937/2469-5750/1510131
- ClinicalTrials.gov. The Role of YAP1 in Fibrosis Explored Through Its Local Inhibition With Verteporfin in Surgical Wounds (Geneva). NCT06944249. clinicaltrials.gov/study/NCT06944249
- ClinicalTrials.gov. SCARFREE-001: Intradermal Verteporfin for Scar Prevention in Open and Closed Surgical Wounds (Odense University Hospital). NCT07488988. clinicaltrials.gov/study/NCT07488988
- U.S. Food and Drug Administration. VISUDYNE (verteporfin for injection), Prescribing Information. NDA 021119, 2023. accessdata.fda.gov
- Sirks MJ, Subhi Y, Rosenberg N, et al.. Perspectives and Update on the Global Shortage of Verteporfin (Visudyne). Ophthalmology and Therapy, 2024;13(7):1821-1831. pubmed.ncbi.nlm.nih.gov/38753294
Wondering what's possible for your hair?
Send three sharp photos of your hair, from the front, the top and the back. You'll get an honest answer on what can be done, roughly how many grafts it would take and what it costs.
- Free and with no obligation
- Photos are assessed by the clinic's medical team
- Replies usually within an hour in the daytime
A study tells you something about groups. Only a doctor who has seen your photos can say what applies to your hair. The medical team at the clinic at the top of our ranking offers a free assessment.
Goes to the clinic at the top of our ranking.

